Related Experiment Videos
Reactivity of a mouse/human chimeric anti-GM2 antibody KM966 with brain tumors
1Division of Biochemistry and Nutrition, International Medical Center of Japan, Tokyo.
Abstract:
With the aim of investigating the passive immunotherapy of brain tumors, we examined the binding of a mouse/human chimeric anti-ganglioside GM2 antibody KM966 to various organs and brain tumors. Frozen sections of 51 surgically resected brain tumors were stained with antibody KM966. Fourteen gliomas out of 16 were stained positively with antibody KM966. Eleven positive sections demonstrated homogenous staining. No specific binding to normal gray matter and white matter was observed. Some cases of meningiomas, neurinomas and metastatic brain tumors were stained with KM966 but with less frequency and intensity than gliomas. In addition, KM966 demonstrated strong antibody-dependent cellular cytotoxicity against human malignant glioma cells. These results showed that antibody KM966 will be useful for passive immunotherapy of malignant gliomas.
Insights
The mouse/human chimeric antibody KM966 shows promising results for passive immunotherapy of brain tumors. It effectively targets malignant gliomas, offering a potential new treatment for these aggressive brain cancers.
Area of Science:
- Oncology
- Immunology
- Neuroscience
Background:
- Brain tumors, particularly malignant gliomas, present significant therapeutic challenges.
- Passive immunotherapy using targeted antibodies is an emerging strategy for cancer treatment.
Purpose of the Study:
- To evaluate the binding specificity and therapeutic potential of the mouse/human chimeric anti-ganglioside GM2 antibody KM966 against brain tumors.
Main Methods:
- Frozen sections of 51 surgically resected brain tumors were stained with KM966.
- Binding affinity and pattern were assessed across various tumor types and normal brain tissue.
- Antibody-dependent cellular cytotoxicity (ADCC) against human malignant glioma cells was evaluated.
Main Results:
- KM966 demonstrated significant binding to 14 out of 16 gliomas, with homogenous staining in 11 cases.
- No specific binding was observed in normal gray or white matter.
- While some binding occurred in meningiomas, neurinomas, and metastatic tumors, it was less frequent and intense than in gliomas.
- KM966 exhibited strong antibody-dependent cellular cytotoxicity against human malignant glioma cells.
Conclusions:
- Antibody KM966 exhibits high specificity for gliomas, sparing normal brain tissue.
- Its ability to induce antibody-dependent cellular cytotoxicity suggests potent anti-tumor activity.
- KM966 holds significant promise as a therapeutic agent for the passive immunotherapy of malignant gliomas.